Previous studies from Reiterer et al. showed that STYX can bind to the F-box domain of FBXW7 in breast cancer, thereby preventing FBXW7 from the formation of SCFFBXW7 complex and further inhibiting FBXW7 activity to degrade its target substrates [8]. Here, FBXW7 is linked to breast carcinoma.